ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Magnesium Chloride

Also written as “Custodiol” and “Nalmefene + 0.94% MgCl2”.

Its studies are mostly in Opiate Overdose · Diabetes Mellitus, Type 1 · Aortic Valve Disease · Heart Failure · Coronary Artery Disease, led by 4 companies.

Drug pageMagnesium Chloride: every studyAll 25 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Feb 14, 20147 company-led studies, 1 open or runningNext primary completion: Jan 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Dr. F. Köhler Chemieits history only41 open or runningphase 3since Feb 14, 2014Sep 29, 2011Jan 2027phase 2 · NCT06032195
Eli Lillyits history only10 open or runningphase 1since Sep 28, 2021Sep 28, 2021none ahead
Knoa Pharmaits history only10 open or runningphase 1since Apr 15, 2026Apr 15, 2026none ahead
Relox Medical10 open or runningphase 3since Jun 30, 2009Jun 30, 2009none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Relox Medical only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 30, 2009First study: phase 3 study in StrokeFirst studyNCT00933868 · 81 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

The one study Relox Medical leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT00933868Stroke · United States3CompletedMay 201081

How it is read

Names in the registry

  • “Custodiol”, 4 entries
  • “Nalmefene + 0.94% MgCl2”, 2 entries
  • “Magnesium Chloride”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.